Primary pulmonary malignant melanoma: Case report and literature review

Shi, Yuequan; Zhu, Bing; Xu, Xiaohui; Cui, Yuming

doi:10.1111/1759-7714.12798

Cited by 14 publications

(16 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kyriakopoulos et al demonstrated the median age of PPMM was 59.1 years old (range from 29 to 90) [2,11]. There were 21 men and 19 women in the population.…”

Section: Discussionmentioning

confidence: 99%

“…The overall outcome of primary pulmonary malignant melanoma was very dismal and 65% of patients survived up to 18 months. Only two patients survived for a long time (10 and 11 years, respectively) [2]. As with other types of tumors, a better prognosis can be obtained through early discovery.…”

Section: Discussionmentioning

confidence: 99%

“…Different types of chemotherapy and immunotherapy as well as radiotherapy have been attempted for MM patients, but no postoperative adjuvant therapy has a good effect on PPMM patients [11,18]. About 40 to 60% of skin melanomas carry BRAF gene mutations (V600E), which causes downstream signals continuous activation through the MAPK pathway [2,13,19]. The FDA approved a range of BRAF inhibitors, including vemurafenib and dabrafenib, as well as MEK inhibitor [20][21][22].…”

Section: Discussionmentioning

confidence: 99%

“…Malignant melanoma (MM) is a malignant neoplasm of the melanocytes, usually arising from the skin. But it may also occur in other mucosal sites and organs [1][2][3]. Primary pulmonary malignant melanoma (PPMM) is extremely rare as only 51 cases have been reported since 1916 [2,4].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Concurrence of primary pulmonary malignant melanoma with invasive pulmonary adenocarcinoma: a case report

Yang

Lei

Zhang

et al. 2020

J Cardiothorac Surg

View full text Add to dashboard Cite

Background: Primary pulmonary malignant melanoma (PPMM) is an extreme rarity in clinic practice, accounting for only 0.01% of all primary pulmonary tumors. And its diagnosis should meet clinical and pathological diagnosis criteria in addition to excluding the possibility of metastatic melanoma. The mainstay of treatment is surgery. The concurrence of primary pulmonary malignant melanoma and invasive pulmonary adenocarcinoma has not been reported before. Case presentation: Herein we report the case of a 39-year-old woman who was asymptomatic and accidently found to have the concurrence of PPMM with invasive pulmonary adenocarcinoma. Before considering the diagnosis of primary pulmonary malignant melanoma, a systemic positron emission tomography-computed tomography (PET-CT) was done to excluding primary tumor metastasis from other sites. The pathological biopsy proved that two lesions in the right middle lobe were invasive pulmonary adenocarcinomas and the mass in the right lower lobe was malignant melanoma. She underwent right middle and lower lobectomy of the lung with mediastinal and hilar lymph dissection. She refused adjuvant chemotherapy, genetic molecular testing or immunotherapy. Fifteen months later she had brain metastasis. Then she received brain radiotherapy and underwent follow-up at the outpatient clinic regularly. Conclusions: We experienced a case of concurrent PPMM and invasive pulmonary adenocarcinoma. The patient reported here is the first case of primary pulmonary malignant melanoma combined with invasive pulmonary adenocarcinoma. This patient remained disease-free 15 months after lung surgery.

show abstract

“…Kyriakopoulos et al demonstrated the median age of PPMM was 59.1 years old (range from 29 to 90) [2,11]. There were 21 men and 19 women in the population.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Concurrence of primary pulmonary malignant melanoma with invasive pulmonary adenocarcinoma: a case report

Yang

Lei

Zhang

et al. 2020

J Cardiothorac Surg

View full text Add to dashboard Cite

show abstract

“…The pathogenesis of PMML remains controversial. There are several theories to explain its occurrence [5][6][7]: (1) melanocytes exist in the whole body as cells of a dispersed neuroendocrine system; (2) melanocytes migrate to the respiratory tract during embryogenesis, where they transform into malignant cancer cells; (3) melanocytes may derive from melanoblasts and produce PMML because they have the same origin as other melanoblasts located in the trachea, oesophagus, and pharynx [8][9][10]; and (4) melanoma cells may originate from pluripotent stem cells. More research is required to clarify the pathogenesis of PMML.…”

Section: Discussionmentioning

confidence: 99%

Primary malignant melanoma of the lung: a case report and literature review

et al. 2020

View full text Add to dashboard Cite

Background: Malignant melanoma (MM) generally presents as a primary neoplasm of the skin, and most MM cases of the respiratory system are metastatic. Primary MM of the lung (PMML) is quite rare, and its diagnosis is relatively difficult. Case presentation: We report the case of a 57-year-old male patient with PMML who denied any history of tumours. His initial complaint was frequent coughs with bloody sputum for 4 days. Chest radiography demonstrated a highdensity shadow in the lower lobe of the right lung, which was suspected to be a large space-occupying lesion on subsequent computed tomography (CT) and to be a hypermetabolic tumour by positron emission tomography-CT. To confirm the diagnosis, exploratory surgery was performed. Finally, we confirmed the diagnosis of PMML. Conclusions: PMML is extremely rare and easily misdiagnosed as lung cancer. Because of its morphological and immunophenotypic variations, the diagnosis of PMML remains difficult. This case report discusses the diagnosis and case management of a patient while referring to the existing literature.

show abstract